CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Preferred Stock Series A	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Balance at Dec. 31, 2010	$ 6,100,528	$ 0	$ 64,382	$ 57,888,506	$ (25,000)	$ (51,827,360)
Balance (in shares) at Dec. 31, 2010		0	64,381,910
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	1,659,083	0	0	1,659,083	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	295,753	0	490	295,263	0	0
Exercise of stock options (in shares)		0	490,000
Sale or offering of common stock and warrants, net of costs and expenses	3,730,587	0	3,779	3,726,808	0	0
Sale or offering of common stock and warrants, net of costs and expenses (in shares)		0	3,778,321
Common stock issued for the conversion of convertible debt	406,663	0	406	406,257	0	0
Common stock issued for the conversion of convertible debt (in shares)	406,664	0	406,664
Common stock issued for the acquisition of Surgical Biologics, LLC	7,087,500	0	5,250	7,082,250	0	0
Common stock issued for the acquisition of Surgical Biologics, LLC (in shares)		0	5,250,000
Beneficial conversion feature recognized on convertible debt	2,715,552	0	0	2,715,552	0	0
Warrants issued in conjunction with convertible promissory notes	14,885	0	0	14,885	0	0
Common stock issued for accrued director fees	0
Common stock issued for earn-out liability	0
Discount on beneficial conversion feature	80,000	0	0	80,000	0	0
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	0
Net income (loss)	(10,193,986)	0	0	0	0	(10,193,986)
Balance at Dec. 31, 2011	11,896,565	0	74,307	73,868,604	(25,000)	(62,021,346)
Balance (in shares) at Dec. 31, 2011		0	74,306,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,538,721	0	0	2,538,721	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	1,052,668	0	844	1,051,824	0	0
Exercise of stock options (in shares)		0	843,863
Common stock issued for the conversion of convertible debt	0
Exercise of warrants	6,001,063	0	7,960	5,993,103	0	0
Exercise of warrants (in shares)		0	7,959,767
Repurchase warrants	(568)	0	0	(568)	0	0
Repurchase warrants (in shares)		0	0
Cashless exercise of warrants	0	0	216	(216)	0	0
Cashless exercise of warrants (in shares)		0	216,085
Common stock issued for accrued director fees	184,653	0	167	184,486	0	0
Common stock issued for accrued director fees (in shares)		0	167,086
Common stock issued for earn-out liability	3,185,223	0	2,632	3,182,591	0	0
Common stock issued for earn-out liability (in shares)	2,632,576	0	2,632,576
Discount on beneficial conversion feature	514,456	0	0	514,456	0	0
Common stock issued for acquisition note	893,267	0	893	892,374	0	0
Common stock issued for acquisition note (in shares)	893,267	0	893,267
Conversion of line of credit with related party	1,403,630	0	1,404	1,402,226	0	0
Conversion of line of credit with related party (in shares)	1,403,630	0	1,403,630
Net income (loss)	(7,662,376)	0	0	0	0	(7,662,376)
Balance at Dec. 31, 2012	20,007,302	0	88,423	89,627,601	(25,000)	(69,683,722)
Balance (in shares) at Dec. 31, 2012		0	88,423,169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,009,176	0	0	6,009,176	0	0
Share-based compensation expense (in shares)		0	0
Exercise of stock options	1,981,418	0	1,959	1,979,459	0	0
Exercise of stock options (in shares)	1,958,674	0	1,958,674
Sale or offering of common stock and warrants, net of costs and expenses	36,509,810	0	5,750	36,504,060	0	0
Sale or offering of common stock and warrants, net of costs and expenses (in shares)		0	5,750,000
Common stock issued for the conversion of convertible debt	5,272,004	0	5,272	5,266,732	0	0
Common stock issued for the conversion of convertible debt (in shares)	5,272,004	0	5,272,004
Exercise of warrants	2,107,883	0	1,844	2,106,039	0	0
Exercise of warrants (in shares)		0	1,844,352
Common stock issued for accrued director fees	0
Common stock issued for earn-out liability	5,792,330	0	1,175	5,791,155	0	0
Common stock issued for earn-out liability (in shares)	1,174,915	0	1,174,915
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	0
Issuance of restricted stock	0	0	3	(3)	0	0
Issuance of restricted stock (in shares)		0	2,500
Net income (loss)	(4,111,853)	0	0	0	0	(4,111,853)
Balance at Dec. 31, 2013	73,568,070	0	104,426	147,284,219	(25,000)	(73,795,575)
Balance (in shares) at Dec. 31, 2013		0	104,425,614
Balance at Nov. 30, 2013
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale or offering of common stock and warrants, net of costs and expenses (in shares)			5,750,000
Balance at Dec. 31, 2013			$ 104,426
Balance (in shares) at Dec. 31, 2013			104,425,614